Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 301–400 of 769
Lantero‐Rodriguez, J., Vrillon, A., Fernández‐Lebrero, A., Ortiz‐Romero, P., Snellman, A., Montoliu‐Gaya, L., Brum, W. S., Cognat, E., Dumurgier, J., Puig‐Pijoan, A., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01201-0 · Cited by 18
Self-citationComparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
Bali, D., Salvadó, G., Beach, T. G., Serrano, G. E., Atri, A., Reiman, E. M., Jeromin, A., Hansson, O., & Janelidze, S. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02064-2 · Cited by 17
Bucci, M., Almkvist, O., Blūma, M., Ashton, N. J., Savitcheva, I., Chiotis, K., Molfetta, G. D., Blennow, K., Zetterberg, H., & Nordberg, A. K. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70182 · Cited by 17
Self-citationPlasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome
Huber, H., Arranz, J., Arslan, B., Leuzy, A., Kittel, O., Molfetta, G. D., Benejam, B., Videla, L., Barroeta, I., Soriano, L. D. H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65882-x · Cited by 17
Self-citationFang, L., Jiao, B., Liu, X., Wang, Z., Yuan, P., Zhou, H., Xiao, X., Cao, L., Guo, J., Tang, B., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.018 · Cited by 17
Consensus on rapid screening for prodromal Alzheimer’s disease in China
Huang, L., Li, Q., Lu, Y., Pan, F., Cui, L., Wang, Y., Miao, Y., Chen, T., Li, Y., Wu, J., et al. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101310 · Cited by 17
Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024) · Molecules · doi:10.3390/molecules29030722 · Cited by 17
Li, L.-J., Sun, X., Huang, Y., Lü, S., Xu, Y., Yang, J., Xie, X.-X., Zhu, J., Niu, X., Wang, D., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00427-8 · Cited by 17
Nuytemans, K., Franzen, S., Broce, I., Caramelli, P., Ellajosyula, R., Finger, E. C., Gupta, V. B., Gupta, V., Illán‐Gala, I., Loi, S. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14312 · Cited by 17
Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials
Marotta, C., Sinclair, B., O'Brien, T. J., & Vivash, L. E. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf022 · Cited by 17
Hirota, Y., Sakakibara, Y., Morishima, M., Sano, T., Hara, M., Arakawa, A., Takao, M., Murayama, S., Saito, Y., Sekiya, M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116203 · Cited by 17
Snellman, A., Ekblad, L. L., Koivumäki, M., Lindgrén, N., Tuisku, J., Perälä, M., Kallio, L., Lehtonen, R., Saunavaara, V., Saunavaara, J. P., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.826423 · Cited by 17
Self-citationInsights into Biomarkers of Alzheimer's Disease: From Core Markers to Emerging Directions
Zhu, W., Wang, Y., Qin, M., Zhao, Q., Feng, L., & Li, M. (2025) · Aging and Disease · doi:10.14336/ad.2025.0761 · Cited by 15
Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz
Hansen, N., Rauter, C. M., & Wiltfang, J. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1839-6237 · Cited by 16
Arthur, E., Ravichandran, S., Snyder, P. J., Alber, J., Strenger, J. R., Bittner, A. K., Khankan, R., Adams, S. L., Putnam, N., Lypka, K. R., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01312-8 · Cited by 16
Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV
Li, X., Yucel, R. M., Clervius, H., Kamalakar, K., Zetterberg, H., Blennow, K., Zhang, J., Adimora, A. A., Collins, L. F., Fischl, M. A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.44194 · Cited by 16
Self-citationMilán, J. A. S., Fernández‐Rhodes, M., Guo, X., Mulet, M., Ngan, S. C., Iyappan, R., Katoueezadeh, M., Sze, S. K., Serra, A., & Gallart‐Palau, X. (2023) · Aging Cell · doi:10.1111/acel.14062 · Cited by 16
Ma, L., Wang, J., Zhou, R., Chen, M., Huang, Z., & Lin, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528919 · Cited by 16
Blood biomarkers for clinical applications in Alzheimer's disease: A narrative review
Li, H., & Wang, Z. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100078 · Cited by 17
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2025) · Neurología (English Edition) · doi:10.1016/j.nrleng.2025.07.004 · Cited by 16
Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid
Klafki, H., Wirths, O., Mollenhauer, B., Liepold, T., Rieper, P., Esselmann, H., Vogelgsang, J. S., Wiltfang, J., & Jahn, O. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15571 · Cited by 16
Investigating the use of plasma pTau181 in retired contact sports athletes
Vasilevskaya, A., Taghdiri, F., Multani, N., Ozzoude, M., Tarazi, A., Khodadadi, M., Wennberg, R. A., Rusjan, P., Houle, S., Green, R., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11223-7 · Cited by 16
Self-citationvan Egmond, L. T., Bukhari, S. H., Benedet, A. L., Ashton, N. J., Meth, E. M. S., Boukas, A., Engström, J., Ilemosoglou, M., Blennow, K., Zetterberg, H., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02146-y · Cited by 16
Self-citationWeiner, S., Blennow, K., Zetterberg, H., & Gobom, J. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2255752 · Cited by 16
Self-citationMomeni, F., Shahbazi‐Gahrouei, D., Mahmoudi, T., & Mehdizadeh, A. (2025) · Diagnostics · doi:10.3390/diagnostics15030360 · Cited by 15
Zhan, X., Wen, G., Wu, X., & Li, J. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00490-9 · Cited by 15
Circulating Biomarkers for the Early Diagnosis of Alzheimer’s Disease
Nunkoo, V. S., Jurcău, A., Les, M., Cristian, A., Militaru, M., Marge, C., Iovanovici, D. C., & Jurcău, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157268 · Cited by 15
Post-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use
Luo, Y. R., Yeung, P. S.-W., Mann, M. W., Zhang, L., Yang, Y. K., & Hoofnagle, A. N. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf094 · Cited by 15
Benedet, A. L., Arslan, B., Tan, K., Huber, H., Pola, I., Molfetta, G. D., Kvartsberg, H., Dolado, A. O., Janelidze, S., Blennow, K., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf162 · Cited by 15
Self-citationVrillon, A., Spina, S., Mejía‐Perez, J. A., LaMore, T., Yballa, C., Soleimani‐Meigooni, D. N., Blazhenets, G., Boxer, A. L., Rojas, J. C., Lago, A. L., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214576 · Cited by 15
Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease
Lilek, J. N., Ajroud, K., Feldman, A. Z., Krishnamachari, S., Ghourchian, S., Gefen, T. D., Spencer, C., Kawles, A., Mao, Q., Tranovich, J. F., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220848 · Cited by 15
Harding, A., Kanagasingam, S., Welbury, R. R., & Singhrao, S. K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-96881-6_13 · Cited by 15
Biofluid biomarkers for Alzheimer’s disease: past, present, and future
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024) · Medical Review · doi:10.1515/mr-2023-0071 · Cited by 14
Cacciaglia, R., Falcón, C., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Alomà, M. M., Suárez‐Calvet, M., Molinuevo, J. L., Fauria, K., Minguillón, C., Kollmorgen, G., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14415 · Cited by 14
Self-citationRong, X., Yao, X., Fang, H., Saji, J., Qian, Y., Gu, J.-X., Yang, M., Peng, W., Liu, C.-R., Chen, B., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01869-6 · Cited by 14
Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion
Eldem, E., Barve, A., Sallin, O., Foucras, S., Annoni, J., Schmid, A. W., & Alberi, L. A. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210056 · Cited by 14
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300063 · Cited by 14
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s
Salvadó, G., Horie, K., Barthélemy, N. R., Vogel, J. W., Binette, A. P., Chen, C. D., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.075367 · Cited by 14
Anton, P. E., Maphis, N. M., Linsenbardt, D. N., & Coleman, L. G. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-81908-7_10 · Cited by 13
The interactome of tau phosphorylated at T217 in Alzheimer’s disease human brain tissue
Kavanagh, T., Thierry, M., Balcomb, K., Ponce, J., Kanshin, E., Tapia-Sealey, A., Halliday, G. M., Ueberheide, B. M., Wısnıewskı, T., & Drummond, E. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02881-8 · Cited by 13
LC‐MS/MS proteomics identifies plasma proteins related to cognition over 9‐year follow‐up
Kresge, H. A., Patterson, K. L., Libby, J. B., Sun, Y., Zhang, P., Liu, D., Robb, W. H., Peterson, A. J., Cole, K. R., Arul, A. B., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70276 · Cited by 13
Self-citationPlasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Dresse, M. T., Ferreira, P. C. L., Prasadan, A., Diaz, J. L., Zeng, X., Bellaver, B., Povala, G., Villemagne, V. L., Kamboh, M. I., Cohen, A. D., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01803-w · Cited by 13
Self-citationZhai, N., Ling, X., Huang, Y., Qiu, Y., Wang, C., Huang, C., Yan, L., Chen, Y., Xiao, Q., Luo, J., et al. (2025) · ACS Sensors · doi:10.1021/acssensors.5c00895 · Cited by 13
Milà‐Alomà, M., Hulle, C. V., Brugulat‐Serrat, A., Brodu, M. M. C., González‐Escalante, A., Sánchez‐Benavides, G., Shekari, M., Castro‐Aldrete, L., Minguillón, C., Martínková, J., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01844-1 · Cited by 13
Daniilidou, M., Öhlund‐Wistbacka, U., Hagman, G., Rosenberg, A., Ashton, N. J., Zetterberg, H., Blennow, K., Matton, A., & Kivipelto, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70931 · Cited by 13
Self-citationCollij, L. E., Salvadó, G., Horie, K., Barthélemy, N. R., Betthauser, T. J., Strandberg, O. T., Smith, R. A., Palmqvist, S., Schindler, S. E., Ossenkoppele, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71732-1 · Cited by 13
Emmerson, J. T., Carmo, S. D., Liu, Y., Shalhoub, A., Ai, L., Bonomo, Q., Malcolm, J. C., Breuillaud, L., & Cuello, A. C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106227 · Cited by 13
Du, J., Tian, H., Fu, M., Yan, Y., Wang, C., & Ding, C. (2022) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2022.112066 · Cited by 13
Many faces and functions of GSKIP: a temporospatial regulation view
Wu, N.-S., Lin, Y., Ma, I. C., Ko, H.-J., & Hong, Y. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110391 · Cited by 13
Emeršič, A., Ashton, N. J., Vrillon, A., Lantero‐Rodriguez, J., Mlakar, J., Kramberger, M. G., González‐Ortiz, F., Kac, P. R., Dulewicz, M., Hanrieder, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13907 · Cited by 12
Self-citationSuárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2024) · Neurología · doi:10.1016/j.nrl.2024.08.002 · Cited by 12
Plasma N‐terminal tau fragment is an amyloid‐dependent biomarker in Alzheimer's disease
Lan, G., Zhang, L., Li, A., Ran, W., Lv, J., González‐Ortiz, F., Cai, Y. Q., Sun, P., Liu, L., Yang, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14550 · Cited by 12
Self-citationTau biomarkers for neurodegenerative diseases: Current state and perspectives
Vacchi, E., Ruíz‐Barrio, I., & Melli, G. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107772 · Cited by 12
Platelets: A new therapeutic target for neurological diseases
Wei, X., & Tang, X.-Q. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102874 · Cited by 12
Roh, H. W., Chang, Y. Y., Kim, K. Y., Jeon, S. Y., Wang, S., Kim, E., Bae, J. N., & Ryu, S. (2026) · Psychiatry Investigation · doi:10.30773/pi.2025.0400 · Cited by 12
Lu, K. P., & Zhou, X. Z. (2024) · Science Signaling · doi:10.1126/scisignal.adi8743 · Cited by 12
Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94
Michalowska, M. M., Herholz, K., Hinz, R., Amadi, C., McInnes, L., Anton-Rodriguez, J. M., Karikari, T. K., Blennow, K., Zetterberg, H., Ashton, N. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01685-6 · Cited by 11
Self-citationBlood-based biomarkers of Alzheimer’s disease—A guideline for clinical use
Shi, J., Ou, Q., & Chen, X. (2024) · Medicine Plus · doi:10.1016/j.medp.2024.100057 · Cited by 11
Sehrawat, A., Zeng, X., Abrahamson, E. E., Deek, R. A., Gogola, A., Kamboh, M. I., Pascoal, T. A., Villemagne, V. L., López, O. L., Ikonomović, M. D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70409 · Cited by 11
Self-citationMontoliu‐Gaya, L., Valeriano-Lorenzo, E., Ashton, N. J., López‐González, F. J., Lantero‐Rodriguez, J., Ruiz-González, A., Pastor, A. B., Frades, B., Zea‐Sevilla, M. A., Valentí, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70562 · Cited by 11
Self-citationPlasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum
Woo, K. A., Yoon, E. J., Kim, R., Kim, H., Kim, S.-Y., Jin, B., Lee, S., Kim, Y. K., Nam, H., & Lee, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70788 · Cited by 11
Li, F., Wu, L., Feng, X., Li, Y., & Fan, H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010070 · Cited by 11
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 12
Self-citationLockhart, S. N., Sutphen, C. L., Tanley, J. E., González‐Ortiz, F., Kac, P. R., Habes, M., Heckbert, S. R., Ashton, N. J., Mielke, M. M., Koeppe, R. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71131 · Cited by 11
Self-citationHirota, Y., Sakakibara, Y., Takei, K., Nishijima, R., Sekiya, M., & Iijima, K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230121 · Cited by 11
Phosphorylated tau in Alzheimer’s disease
Telser, J., Grossmann, K., Wohlwend, N., Risch, L., Saely, C. H., & Werner, P. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.05.001 · Cited by 11
Green, Z. D., Kueck, P. J., John, C. S., Burns, J. M., & Morris, J. K. (2023) · Current Alzheimer Research · doi:10.2174/0115672050271523231111192725 · Cited by 11
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 11
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 11
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01474-z · Cited by 11
Self-citationClinical significance of plasma candidate biomarkers of Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Kornhuber, J., & Mroczko, B. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.100675 · Cited by 11
Sitnikova, V., Nurkhametova, D., Braidotti, N., Ciubotaru, C. D., Giudice, L., Impola, U., Kärkkäinen, S., Kalapudas, J., Penttilä, E., Löppönen, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70368 · Cited by 11
Self-citationCampese, N., Beatino, M. F., Gamba, C. D., Belli, E., Giampietri, L., Prete, E. D., Galgani, A., Vergallo, A., Siciliano, G., Ceravolo, R., et al. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1965879 · Cited by 11
Platelet TAU is Associated with Changes in Depression and Alzheimer's Disease
Sarg, B., Korde, D. S., Marksteiner, J., & Humpel, C. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705153 · Cited by 11
Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease
Tournier, B. B., Ceyzériat, K., Marteyn, A., Amossé, Q., Badina, A. M., Tsartsalis, S., Herrmann, F. R., Zekry, D., & Millet, P. (2024) · Brain Pathology · doi:10.1111/bpa.13281 · Cited by 10
Sekiya, M., Sakakibara, Y., Hirota, Y., Ito, N., Chikamatsu, S., Takei, K., Nishijima, R., & Iijima, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106694 · Cited by 10
Sharmin, T., Chatterjee, P., Doecke, J. D., Ashton, N. J., Huynh, K., Pedrini, S., Sohrabi, H. R., Heng, B., Eslick, S., Zetterberg, H., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16244 · Cited by 10
Self-citationMao, X., Wang, Y., Luan, Y., Wang, Y., Wang, J., Dai, W., Guan, Y., Huang, Q., Gunn, R. N., Ossenkoppele, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00906-0 · Cited by 10
Tang, F., Wei, J., Wong, M.-L., & Lei, P. (2025) · Genomic psychiatry : · doi:10.61373/gp025i.0122 · Cited by 10
Babygirija, R., Green, C. L., Sonsalla, M. M., Le, I. M. F., Xiao, F., Yandell, S., Calubag, M. F., Trautman, M. E., Tobon, A., Matoska, R., et al. (2026) · Advanced Science · doi:10.1002/advs.202515220 · Cited by 10
CSF p-tau231: A biomarker for early preclinical Alzheimer?
Suárez‐Calvet, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103936 · Cited by 10
Li, C., Chen, T., Peng, P.-L., & Lin, C. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11301-w · Cited by 10
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease
Gaetani, L., Chiasserini, D., Paoletti, F. P., Bellomo, G., & Parnetti, L. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2276918 · Cited by 10
Wennström, M., Schultz, N., Gallardo, P. M., Bank, T. N. B., Serrano, G. E., Beach, T. G., Bose, S., & Hansson, O. (2024) · Cells · doi:10.3390/cells13040331 · Cited by 10
Emeršič, A., Karikari, T. K., Kac, P. R., González‐Ortiz, F., Dulewicz, M., Ashton, N. J., Jakob, G. B., Ledinek, A. H., Hanrieder, J., Zetterberg, H., et al. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105801 · Cited by 10
Self-citationKazemi, M., Sadeh, R. N., Khaniani, M. S., Rezazadeh, M., Derakhshan, S. M., & Ghafouri‐Fard, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-82490-9 · Cited by 10
Prospective evaluation of plasma phosphorylated tau in a real‐life memory clinic in Thailand
Thanapornsangsuth, P., Booncharoen, K., Luechaipanit, W., Supharatpariyakorn, T., Sarutikriangkri, Y., Tangnimitchok, S., Likitjaroen, Y., Sukprakun, C., Tepmongkol, S., & Hemachudha, T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13022 · Cited by 10
Qiu, Y., Jacobs, D. M., Messer, K. S., Salmon, D. P., Wellington, C. L., Stukas, S. K., Revta, C., Brewer, J. B., Léger, G. C., Askew, B., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01745-3 · Cited by 9
Wu, L., Arvai, S., Wang, S. J., Liu, A., & Xu, B. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1288930 · Cited by 9
Qiu, C., Li, Z., Leigh, D. A., Duan, B., Stucky, J. E., Kim, N., Xie, G., Lu, K. P., & Zhou, X. Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1343962 · Cited by 9
Zhao, L., Zhang, M., Li, Q., Wang, X., Lu, J., Han, Y., & Cai, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01983 · Cited by 9
Budak, M., Fausto, B. A., Osiecka, Z., Sheikh, M., Perna, R., Ashton, N. J., Blennow, K., Zetterberg, H., Fitzgerald-Bocarsly, P. A., & Gluck, M. A. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01619-0 · Cited by 9
Self-citationWhat contribution can genetics make to predict the risk of Alzheimer's disease?
Schramm, C., Wallon, D., Nicolas, G., & Charbonnier, C. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.005 · Cited by 9
A blood mRNA panel that differentiates Alzheimer’s disease from other dementia types
Fu, X., Chu, C., Pang, Y., Cai, H., Ren, Z., & Jia, L. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11558-9 · Cited by 9
Achard, V., Ceyzériat, K., Tournier, B. B., Frisoni, G. B., Garibotto, V., & Zilli, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734881 · Cited by 9
Ashton, N. J., Molfetta, G. D., Tan, K., Blennow, K., Zetterberg, H., & Messing, A. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07495-8 · Cited by 8
Self-citationEmerging blood biomarkers in Alzheimer’s disease: a proteomic perspective
Patel, N. K., Agrawal, N., Mishra, R., Rekha, M. M., Nayak, P. P., Kaur, M., Khachi, A., Goyal, K., Rekha, A., Rana, M., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120397 · Cited by 8
Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Sauer, M., Gomes, B. F., Shahrouki, P., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Camporesi, E., Belbin, O., Alcolea, D. A., Kumar, A., Sharma, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70241 · Cited by 8
Self-citationImpact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease
Gogola, A., Zeng, X., Williams, L. A., Chapple‐McGruder, T., Saeed, A., Lopresti, B. J., Snitz, B. E., Tudorascu, D. L., Minhas, D. S., Ikonomović, M. D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70463 · Cited by 8
Self-citationFrom Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer’s Disease Landscape
Bougea, A. M., Debasa‐Mouce, M., Gulkarov, S., Castro‐Mosquera, M., Reiss, A. B., & Ouro, A. (2025) · Medicina · doi:10.3390/medicina61081462 · Cited by 8
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.